Introduction
The term ataxia refers to the loss of body balance and coordination while performing movements 1 . Conventionally, the autosomal dominant inherited ataxia is called spinocerebellar ataxia (SCA) 2 . Typical clinical features of SCAs are gait ataxia, appendicular ataxia followed by dysarthria, ocular difficulties in moving surrounding like saccadic eye movement, diplopia. Noncerebellar eye movement abnormalities are ocular "stare", blepharospasm, gaze palsies, ptosis and slowed saccades. Intention tremor on the finger to nose testing, dysmetria, widened stance and difficulty with gait, mainly when turning and rebound phenomena are characteristic cerebellar abnormalities 3 .
The age of onset of disease is variable usually it is adult onset 4 . The worldwide prevalence of Autosomal dominant spinocerebellar ataxia is found to be 1to 5 cases per 100,000 population 5, 6 . Among all SCAs, SCA 3 is most common type which also known as Machado-Joseph disease (MJD) followed by SCA 1, 2, 6 and 7 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . The site of mutation in different regions of the genome responsible for the numerous SCA types, several of the gene associated with this mutant site have already identified. Based upon the types of mutations, SCAs are categorized in 3 main group, group 1st is refers to SCAs with expanded CAG/polyQ ataxia, nonprotein coding repeat expansion ataxia comes under 2nd group and SCAs with conventional mutations (deletion, insertion, duplication, frameshift, and missense) kept in group 3rd. In SCAs most coalescing feature is a pattern of neurodegeneration, often clinician associate the disorder with clinical features which reflects the region of brain damage. 3 A growing body of evidence suggest the similar molecular mechanism behind the disease as other neurodegenerative diseases. Although based upon the types of mutation SCAs kept in 3 group but on the basis of genetic mechanism of disease, SCAs falls into four categories. Here it is noteworthy that the above 4 categories is for those SCAs in which the responsible gene has been identified already. The first category is SCAs with exonic triplet CAG repeats, for instance, SCA 1, 2, 3, 6, 7, 17, dentatorubropallidoluysian atrophy (DRPLA), and SCA 8 (partly), these codes for long, abnormal polyglutamine tracts within translated protein and results in a gain of toxic functions to these translated proteins. The second category is of SCAs with intronic or non-coding repeat expansion SCA 10, 12, 31, 36 and SCA 8(partly), some of these may involve in RNA-mediated toxicity. SCA 5, 11, 13, 14, 19/22, 23, 26, 27, 28, 29, and 35 with point mutations (including small insertions or deletions) may involve in a gain of novel function, haploinsufficiency or even dominant negative effect classified in category three of classification of the genetic mechanism. In last category the 4th one, SCAs with large duplications or deletions as SCA 15 and 20 have kept, they may result in gene dosage mechanisms i.e. under or over translation of the relevant protein products. 
Historical Perspective
The earliest practice of designating a disease with the term ataxia originate in the middle of the 19th century when Tabes dorsalis is named as Locomotor ataxia (a clinical term) by the French neurologist Duchenne de Boulogne. Autosomal dominant hereditary ataxia is referred as SCA, SCAs have assigned a different number based on its order of discovery. The term spinocerebellar ataxia first used in 1950 was based on the model of Friedreich ataxia. In the year, 1993 discovery of unstable CAG trinucleotide repeat expansion in SCA 1 disorder opens the way for the identification of mutations behind other autosomal dominant inherited SCAs. The method used previously for the identification and analysis of disease was linkage analysis. Gene discovery is the most recent method of identification of disorder. In the 20th century classification and neuropathological approaches to ataxia was based on the pivotal work of Greenfield and Holmes. The classification categories were based on the neuropathological characters such as spinocerebellar degeneration, or cerebellar cortical atrophy, olivopontocerebellar atrophy. However, this classification was not proper and the general consensus acceptance never reached. A new classification done by the professor Anita Harding in the beginning of 80s of the 20th century change the situation. SCAs were classified into four different types by Harding based on the specific characteristics, the four types are given as follows: The characteristics associated with Type 1 were cerebellar ataxia with optic atrophy, dementia, ophthalmoplegia, extrapyramidal signs, and amyotrophy. Disease symptoms ophthalmoplegia and extrapyramidal signs with retinal degeneration were kept in Type 2. The third category of classification (Type 3) was implicated with pure cerebellar ataxia. Type 4 was defined with the symptoms myoclonia and deafness in addition to cerebellar ataxia. Figure-1 exhibit most important events of ataxia on the historical timeline. 
Symptoms and Visible Characteristics
SCAs are a group of complex disease which is heterogeneous in genotypic as well as phenotypic sense. The phenotypic heterogeneity implies that the different phenotype is determined by the same genotype, genotypic heterogeneity defined as the presence of the same phenotype although the genotypes are different. 24 The modern or new classification of ataxia is based on the order of discovery of locus of mutation. The number of genes have determined which implicated with these discovered locus although few of them yet to be determined, the most common features related to disease are uncoordinated movement, eye and speech impairments, cognitive decline, neuropathy, and spasticity. 4, 25 The current status of genetic testing is limited and cannot offer testing for all types of ataxia. The initial decision of genetic testing for a particular type of ataxia based on the clinical features that differentiate among many types, patient disease history and family disease history. 
Methods for screening of SCAs
Numerous methods of identification of different types of SCAs applied in hospitals and research laboratory for screening, Figure-2 
Electrophysiological
The basis of this method is an electrophysiological measurement of masseter reflex. The initial study was done on the patients of SCA type 2 and 3 by Antonio Garcia et al., the device used for the study was electromyography (EMG) system (Medelec-Synergy EMG/PE; Cardinal Health, UK). Masseter reflex measurement is a reliable test that discriminates between the SCA type 2 and 3, although this method was used for primary screening purpose. 
Radiological
A study carried by Yoshio Murata et al. found the certain characteristics feature of the brain of MJD patients in MRI study. The MRI study demonstrates the atrophy of temporal and frontal lobe in addition to Globus pallidus, abnormality in afferent and efferent cerebellar tracts also reported. These features may helpful in finding difference between sporadic olivopontocerebellar atrophy (sOPCA) and MJD. 28 Another published work of Yoshio Murata et al. signify the distinguishable feature of SCA 6 from other SCAs forms, in an MRI study of the brain. The MRI study shows the affected cerebellar region and its afferent and efferent system. 29 MRI is the steadfast method to find the affected brain regions in SCAs patient and other neurodegenerative disorder but it is not a confirmatory test for SCAs types, due to several overlap in clinical characteristics.
Biochemical
A study done by Marcelle R. Morrison and Roger N. Rosenberg on the brain of Machado-Joseph disease patients led the finding that there were an elevation in steady state level of many proteins such as glial fibrillary acidic protein complex, J protein complex, and L protein complex in the cerebellar and cortex region of brain in comparison to the control brain protein analysis. The specific pathological features observed in patients with SCA 1, SCA 2, SCA 3 and SCA 6 provide a stepping stone for the identification of disorder among several pathotypes. They observed no significant change in the striatal [11C]dMP binding potential (BPdMP) but reduce rCMRglu in the cerebellum and brain stem of SCA 1 patients. . In SCA 2 patient's striatal BPdMP was evidently reduced, putamen and caudate nucleus region showed the 57 and 55% of BPdMP reduction respectively. An increment in the rCMRglu was noted in the temporal cortical region of interest (ROI) analysis. The dopamine terminal (DAT) loss was throughout striatum and similar to PD with a more severely affected putamen. Particularly in the case of SCA 2 mutation, the dopaminergic system was sensitive. Pathological features of SCA 3 demonstrated the marked reduction of striatal BPdMP. The same degree of reduction of BPdMP in the putamen (29%) and caudate (20%) were observed. Brainstem, Thalamus and putamen region of brain displayed, the reduce level of rCMRglu, the area of decreased metabolism extended from cerebellar midline structures to adjacent pons and midbrain. An increased metabolism was observed in the superior and middle temporal gyri. The loss of DAT observed in SCA 3 patients but it was less severe in comparison to patients with SCA 2. The loss of dopaminergic cells and global synaptic impairment might contribute to the alterations of DATs in SCA 3 patients. Reduced rCMRglu level was observed in the putamen region of patients with SCA 6. Differentiated brain regions with the increase and decrease metabolic activity were observed in temporal gyri (superior, middle) and Cerebellum respectively in patients with SCA 6. 
Molecular and Genetic
Molecular and genetic testing techniques depend on the diverse types of mutation implicated in different SCAs types. The most common type of mutation is trinucleotide (CAG) repeats found in coding regions of genes in SCA 1, 2, 3, 6, 7, 17 and DRPLA. Bidirectional transcribed CTG and CAG repeats in 3'UTR ATXN8OS region as well as ORF ATXN8 region found in SCA 8. The nontranslated mutation found in SCA 10, SCA 12 and SCA 31, pentanucleotide repeat ATTCT and TGGAA found in the intronic region of SCA 10 and SCA31 respectively, CAG repeats present in 5'UTR of SCA 12. Hexanucleotide repeats GGCCTG found in the intronic region of genes in SCA 36. The conventional mutations (missense, deletion, duplication and frameshift) has reported in SCA type 5, 11, 13, 14, 15, 16, 20, 21, 23, 26, 27, 28, 29, 34, 35, 38, 40 and 42 and DRPLA. 23, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Table- 2 demonstrate the particular mutation and associated SCAs types. The most reliable and popular method of screening of spinocerebellar ataxia is Genetic diagnosis which relies upon Genetic material DNA and molecular techniques. The molecular genetic screening method used in different parts of the world in various races of Human population. In most of the SCAs where the mutation is due to nucleotides repeats, PCR screening technique is used to amplify the mutated region of the genomic fragment, analysis of amplified region is done with gel electrophoresis or automated sequencer. [51] [52] [53] [54] [55] [56] The other molecular techniques include repeat expansion detection (RED) method, Linkage analysis, Whole-Exome sequencing, Whole genome sequencing and whole mitochondrial sequencing. Kerstin Lindblad et al. used the RED method to detect CAG repeats in SCA 7 patients and in their family, in the RED method they used thermostable DNA ligase to detect repeats directly from DNA. 57 Lourdes Martorell et al. detected CAG/CTG expansion in SCA 1 and MJD patients by using the RED method. 58 The detection of CAG repeat expansion in MJD patients by RED method demonstrated in another publication by Kerstin Lindblad et al. 59 A published work of Kokoro Ozaki et al. and Je´roˆme Delplanque et al. demonstrate the use of linkage analysis in determination of mutation in SCA 34 and SCA 21 respectively. In the Genome-wide linkage analysis, they used SNP array chip for mutation detection. Most of the SCAs which cannot be identified by molecular techniques such as PCR, RED, and linkage analysis method can identify by Whole exome sequencing, whole genome sequencing or whole mitochondrial sequencing. Sequencing technique most preferably used for the identification of Conventional mutations linked SCAs. 23, 36, 37 Numerous combination of molecular techniques and appliances which also include variants of PCR are used for the genetic screening of SCAs. [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] 
Algorithm for the differential genetic diagnosis of SCAs
Differential genetic diagnosis of SCAs depend upon the number of factors, to proceed for the genetic diagnosis it is very much important that the details of clinical history, family history and outcomes of all neurological examination must be known. The first step is to rule out all the acquired (non-genetic) cause of ataxia such as vitamin deficiencies, multiple sclerosis, vascular disease, primary or metastatic tumors, alcoholism, or paraneoplastic diseases associated with occult carcinoma of the breast, ovary, or lung and then proceed for the genetic testing. Figure-3 describe the steps involve in differential genetic diagnosis of SCAs. Glutamate transport activator (6) Potassium channel modulator and Calcium-activated potassium channel activators. The RNA interference or Antisense oligonucleotide strategies have been used in mouse model of SCA 1, SCA 3 and SCA 7 for silencing of specific mutant allele which leads to the improvement in condition from disease state. It may have relevance for the treatment of SCAs in human subjects. Lymphoblastoid cells derived from SCA 7 patient show reduced expression of Hsp70 and Hsp27, activation of these two proteins may have neuroprotective benefit. In SCA 3 mouse model H3 and H4 histone found to be hypo acetylated it suggest the presence of HDAC over activity, use of HDAC inhibitor Sodium butyrate in SCA 3 mouse model improve Histone acetylation and increase the expression of gene which were suppressed earlier in cerebellum region. HDAC inhibitors may have therapeutic promise for the treatment of some forms of SCA, particularly those which display repressed gene transcription condition. Drug-mediated treatments which increase the glutamate uptake, increase expression of calcium binding proteins, or inhibit intracellular calcium release store and modulate potassium channel might be promising candidates for treating neuronal dysfunction and synaptic physiology across different cause of SCAs. 
Conclusion
This review illustrates the clinical manifestation and available diagnostic methods and treatment of neurodegenerative disorder SCAs. It is very necessary for the individual patients and their family to come to an appropriate diagnosis to confirm the disorder and affected regions of the body. The gold standard test for SCAs is a Molecular and Genetic diagnosis, Although Physiological, Radiological, and Radiochemical methods are not confirmatory tests but it is helpful in the determination of affected brain region and extent of damage occurs to the brain and construction of algorithm for the differential genetic diagnosis of SCAs. These test may also confirm the anticipated consequence to the body as the Nervous system is a master controller of organs and organs associated functions. This review also summarize the outcome of various experimental approaches for the treatment of SCAs. 
